Investing in tomorrow's health: Abu Dhabi's strategic health and life sciences agenda
Abu Dhabi Global Health Week (ADGHW) 2025 showcased the Emirate's bold vision to transform health and life sciences into a powerhouse of innovation, investment, and economic growth. More than a hub for health delivery, Abu Dhabi has positioned itself as a platform for global breakthroughs, where technologists, scientists, investors, and policymakers co-create solutions backed by committed capital, agile regulation, and a unified health ecosystem.
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council and organised by the Department of Health – Abu Dhabi (DoH), this year's edition was anchored around the theme 'Towards Longevity: Redefining Health and Well-being.' The event provided a platform for leaders in policy, technology, finance, and research to explore a new paradigm—one that integrates artificial intelligence (AI), data science, genomics, and patient-centred design to achieve better outcomes.
Abu Dhabi's Evolving Model
At the core of ADGHW 2025 is Abu Dhabi's focus on longevity, prevention, and precision health, driven by advanced technologies and a connected health ecosystem. The Emirate's commitment to personalised care is supported by world-class research centres, integrated data platforms, investment-friendly policies, and forward-thinking regulations.
The launch of the Health, Endurance, Longevity, and Medicine Cluster (HELM) marked a major milestone. Designed to attract international investment and talent, HELM will accelerate Abu Dhabi's transition into a global hub for biotech, MedTech, and life sciences manufacturing. By 2045, the cluster is projected to contribute AED 94 billion (USD 25.6 billion) to GDP and attract AED 42 billion (USD 11.4 billion) in investment. The cluster integrates cutting-edge laboratories, advanced manufacturing facilities, and a supportive regulatory environment to fast-track innovation from lab to market.
'We are building an intelligent health system that embeds AI, genomics, and data-driven insights into every layer of care,' said H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of Department of Health. 'Our vision is globally connected, prevention-first model, delivering personalised impact at scale, supported by strategic investment, bold partnerships, and a unified ecosystem.'
Live Events
Abu Dhabi is cultivating a thriving life sciences sector, evolving from an import-heavy, treatment-oriented model to a regional hub for R&D, clinical innovation, and biotech scale-up. Investors are taking notice.
Complementing HELM, a landmark infrastructure agreement between DoH, the Abu Dhabi Investment Office (ADIO), and Masdar City will establish state-of-the-art life sciences laboratories to enable R&D, support early-stage ventures, and foster academic–industry collaboration. The goal: translate research into commercially viable solutions and grow the life sciences economy from bench to bedside.
E
mbedding Intelligence in Health
The Emirate's vision for health innovation includes significant investment in digital infrastructure and talent. From telehealth to AI-integrated diagnostics and predictive analytics, Abu Dhabi is embedding intelligence across the patient journey—while building a skilled workforce ready to harness emerging technologies.
'Abu Dhabi is not just adopting digital health tools—we're architects of a smart health ecosystem,' said Ibrahim Al Jallaf, Executive Director of Digital Health at Department of Health (DoH). 'By aligning regulation, education, innovation, and investment, we're creating a seamless, data-driven care environment that empowers both clinicians and patients.'
Strategic Health Infrastructure
Abu Dhabi's life sciences push is supported by initiatives that extend beyond innovation to include robust global logistics. A key announcement at ADGHW 2025 was the inauguration of a regional vaccine distribution hub—a major milestone in the Emirate's strategy to strengthen global health supply chains. Building on a 2024 MoU with GSK, the hub leverages Abu Dhabi's strategic location, advanced logistics infrastructure, and strong regulatory frameworks to ensure rapid, equitable access to vaccines across regional and global markets.
This initiative underscores Abu Dhabi's integrated approach to health innovation, where infrastructure, policy, and international collaboration converge to create a future-ready health system that is agile, inclusive, and impact-driven.
Life Sciences as an economic engine
The life sciences sector is fast becoming a cornerstone of Abu Dhabi's economic diversification strategy. Recent projections indicate the sector will contribute over AED 94 billion to GDP by 2045 and create more than 30,000 jobs. With streamlined regulation, strong intellectual property protections, and support for public–private partnerships, Abu Dhabi offers a compelling environment for investors.
Its world-class logistics and distribution networks further enhance its attractiveness as a base for pharmaceutical and MedTech companies looking to scale.
Strengthening global ties
India and Abu Dhabi share strategic interests in health technology and research translation. Ongoing collaborations in digital diagnostics, genomics, and health data governance create space for joint innovation, particularly relevant as both nations invest in technology-led, accessible healthcare models.
Looking ahead
Abu Dhabi is not just building a health system; it is building a future-ready life sciences economy. Through bold policy, cross-sector collaboration, and long-term investment, it is creating a platform where global breakthroughs are enabled and scaled responsibly. In a world seeking resilient, innovative health systems, Abu Dhabi offers a powerful and actionable model for the future of global health innovation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
15 hours ago
- Time of India
Extreme heat speeds up aging as much as smoking and alcohol consumption, reveals study
Image credits: Getty Images If you think extreme heat only makes you feel exhausted and sweaty, a new study will extremely change your beliefs. It has been known that extreme heat raises the risk of heat stroke, cardiovascular disease, kidney diseases and more. Any change in the environment can put pressure on the body and affect its functioning. However, there has been limited research on how environmental stressors influence aging. Now a study published in the journal Science Advances has explored how heat affects biological aging, leading to gradual deterioration of cells and tissues and increasing the risk of age-related diseases. How does rising heat affect the body? Image credits: Getty Images The researchers examined blood samples from over 3,600 older adults across the United States. They measured the participant's biological age using epigenetic clocks that capture DNA modification patterns that change with increasing age. DNA modification or methylation refers to chemical modifications in the DNA that regulate the activeness of genes. Environmental factors can influence this regulation and change how genes function, thus affecting aging and disease risk over time. Results of the research on animal models showed that extreme heat triggered maladaptive epigenetic memory or lasting changes in DNA methylation patterns. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch xu hướng AUD/USD? IC Markets Đăng ký Undo A single episode of extreme heat can lead to long-term changes in DNA methylation across different tissue types in mice. In order to analyse the effects of long periods of extreme heat on people, the researchers linked the epigenetic clock data with climate records to assess whether people residing in hot environments showed faster biological aging. Here, the results stated that older adults residing in areas with frequent hot days presented significantly faster epigenetic aging compared to those who lived in cooler areas. This link between biological age and extreme heat remained constant after analysing various individual and community factors such as physical activity levels and socioeconomic status. Participants living in locations with at least 140 extreme heat days annually (classified as heat days exceeding the index of 90 degrees Fahrenheit), experienced up to 14 months of additional aging compared to those who lived in areas with fewer than 10 such days annually. A key note here is that extreme heat can speed up biological aging as much as smoking and heavy alcohol consumption.
Business Standard
3 days ago
- Business Standard
Lupin launches Prucalopride Tablets in US market
Lupinannounced the launch of Prucalopride Tablets, 1 mg, and 2 mg, in the United States, following the recent approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity) had estimated annual sales of USD 184 million in the U.S. (IQVIA MAT April 2025).
The Hindu
4 days ago
- The Hindu
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028
Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world's first malaria vaccine for children 'RTS,S' developed by GSK, PATH and partners, by more than half to less than USD 5 progressively by 2028. Announced as part of their commitment to the Vaccine Alliance (Gavi), the two companies said the price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. Lower vaccine cost through collaboration The announcement forms part of pledges to Gavi for its next replenishment phase -- Gavi 6.0, 2026-2030 -- by both companies, they said in a joint statement. "This pledge to Gavi 6.0 is more than a pricing announcement. It is a commitment to global equity, innovation, and collaboration. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families," Bharat Biotech International Ltd (BBIL) Executive Chairman Krishna Ella said. Further, he said, "By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria." GSK Chief Global Health Officer Thomas Breuer said the company had partnered with Bharat Biotech in 2021 with a common goal of finding a sustainable solution to get ahead of malaria. "Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO," he said. Breuer added, "This demonstrates our commitment to changing the trajectory of infectious diseases like malaria, making a difference in the lives of children and families across Africa." The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the latest pledge to the Gavi replenishment, he noted. Boosting malaria immunisation drive With Gavi's support, 12 endemic countries in Africa will be introduced to RTS,S through routine immunisation programmes by the end of 2025. RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency and undertake the planned technology transfer to Bharat Biotech, the statement said. In parallel, Bharat Biotech has invested over USD 200 million in new, higher-output manufacturing facilities, product development and technology transfers. "These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete," it added. Gavi, the Vaccine Alliance CEO Sania Nishtar said, "Our ambition is to protect at least 50 million more children across Africa by the end of 2030, and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach."
